Shlomo Noy
Directeur/Membre du Conseil chez Innovalve Bio Medical Ltd.
Profil
Shlomo Noy is currently a Director at Innovalve Bio Medical Ltd.
where he started in 2018.
He previously worked as a Director at Medx Xelerator LP.
Postes actifs de Shlomo Noy
| Sociétés | Poste | Début |
|---|---|---|
Innovalve Bio Medical Ltd.
 Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 09/08/2018 |
Anciens postes connus de Shlomo Noy
| Sociétés | Poste | Fin |
|---|---|---|
Medx Xelerator LP
 Medx Xelerator LP Medical SpecialtiesHealth Technology Medx Xelerator LP provides medical devices incubator. The company is headquartered in Or Yehuda, Israel. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Medx Xelerator LP
Medx Xelerator LP Medical SpecialtiesHealth Technology Medx Xelerator LP provides medical devices incubator. The company is headquartered in Or Yehuda, Israel. | Health Technology |
Innovalve Bio Medical Ltd.
Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Health Technology |
